23andMe Holding Co.

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
0.4829 USD -4.47% Intraday chart for 23andMe Holding Co. +8.96% -47.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
US Equity Markets Close Mixed Thursday MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Sector Update: Health Care MT
News Highlights : Top Company News of the Day - Thursday at 1 PM ET DJ
Top Midday Stories: Taiwan Semiconductor Manufacturing, Blackstone, Elevance Health, D.R. Horton, Infosys and Marsh & McLennan Report Earnings; Tesla's Musk Says Laid-Off Employees Received "Incorrectly Low" Severance; 23andME CEO Mulls Taking Company Private; Northrop Grumman Working with SpaceX on Spy Satellite MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET DJ
23andMe CEO Mulls Plan to Take Company Private MT
23andMe CEO Mulls Plan to Take Company Private MT
23andMe CEO Considering Taking Company Private MT
North American Morning Briefing : Stock Futures Rise After TSMC Earnings DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
23andMe CEO Wojcicki considering taking firm private, filing shows RE
Citigroup Adjusts 23andMe Price Target to $0.47 From $0.85, Maintains Neutral Rating MT
23andMe Holding Co. to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research Annual Meeting 2024 CI
23Andme Holding Co. Announces Management Changes CI
Biggest cyberattacks in US healthcare sector RE
23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 CI
Transcript : 23andMe Holding Co., Q3 2024 Earnings Call, Feb 07, 2024
Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M MT
23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023 CI
23andMe Holding Co. Provides Earnings Guidance for the Year Ending March 31, 2024 CI
23andMe Holding Co. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Chart 23andMe Holding Co.
More charts
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5055 USD
Average target price
1.425 USD
Spread / Average Target
+181.90%
Consensus
  1. Stock Market
  2. Equities
  3. ME Stock
  4. News 23andMe Holding Co.
  5. 23andMe : Reports Narrowed Fiscal First-Quarter Loss, Issues Forecast In-Line With Street Views